The last time I wrote an article on ORIC Pharmaceuticals (NASDAQ:ORIC) it was with respect to a Seeking Alpha article entitled "ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could ...

On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, targeting prostate and lung cancer, but remains in very early clinical stages. Financially, ORIC is well-capitalized for ...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in ...

ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...

In preclinical prostate cancer models, ORIC-944 demonstrated robust inhibition of PRC2, enhanced luminal cell state, and increased androgen receptor (AR) signaling. Analysis of chromatin revealed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...